Detalhe da pesquisa
1.
Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors.
Nature
; 504(7480): 437-40, 2013 Dec 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-24226772
2.
Hydroxyethylamine-based inhibitors of BACE1: P1-P3 macrocyclization can improve potency, selectivity, and cell activity.
Bioorg Med Chem Lett
; 23(15): 4459-64, 2013 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23769639
3.
Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune disease.
J Med Chem
; 58(1): 480-511, 2015 Jan 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-25469863
4.
An Orally Available BACE1 Inhibitor That Affords Robust CNS Aß Reduction without Cardiovascular Liabilities.
ACS Med Chem Lett
; 6(2): 210-5, 2015 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-25699151
5.
Discovery of Small-Molecule Glucokinase Regulatory Protein Modulators That Restore Glucokinase Activity.
J Biomol Screen
; 19(7): 1014-23, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24717911
6.
Inhibitors of ß-site amyloid precursor protein cleaving enzyme (BACE1): identification of (S)-7-(2-fluoropyridin-3-yl)-3-((3-methyloxetan-3-yl)ethynyl)-5'H-spiro[chromeno[2,3-b]pyridine-5,4'-oxazol]-2'-amine (AMG-8718).
J Med Chem
; 57(23): 9811-31, 2014 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-25363711
7.
Lead optimization and modulation of hERG activity in a series of aminooxazoline xanthene ß-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors.
J Med Chem
; 57(23): 9796-810, 2014 Dec 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-25389560
8.
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 1. Discovery of a novel tool compound for in vivo proof-of-concept.
J Med Chem
; 57(2): 309-24, 2014 Jan 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-24405172
9.
Structure- and property-based design of aminooxazoline xanthenes as selective, orally efficacious, and CNS penetrable BACE inhibitors for the treatment of Alzheimer's disease.
J Med Chem
; 55(21): 9156-69, 2012 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-22928914
10.
A Potent and Orally Efficacious, Hydroxyethylamine-Based Inhibitor of ß-Secretase.
ACS Med Chem Lett
; 3(11): 886-91, 2012 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-24900403
11.
Design and preparation of a potent series of hydroxyethylamine containing ß-secretase inhibitors that demonstrate robust reduction of central ß-amyloid.
J Med Chem
; 55(21): 9009-24, 2012 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-22468639
12.
Design and synthesis of potent, orally efficacious hydroxyethylamine derived ß-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors.
J Med Chem
; 55(21): 9025-44, 2012 Nov 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-22468684
13.
Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors.
J Med Chem
; 54(6): 1789-811, 2011 Mar 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-21332118
14.
From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1).
J Med Chem
; 54(16): 5836-57, 2011 Aug 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-21707077
15.
A telomerase enzymatic assay that does not use polymerase chain reaction, radioactivity, or electrophoresis.
Anal Biochem
; 331(2): 230-4, 2004 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15265727